Your browser is no longer supported. Please, upgrade your browser.
Settings
IPCI IntelliPharmaCeutics International Inc. daily Stock Chart
IPCI [NASD]
IntelliPharmaCeutics International Inc.
Index- P/E- EPS (ttm)-3.26 Insider Own56.50% Shs Outstand8.13M Perf Week-5.59%
Market Cap4.07M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float6.52M Perf Month-18.02%
Income-12.50M PEG- EPS next Q0.00 Inst Own0.50% Short Float7.55% Perf Quarter-81.83%
Sales2.40M P/S1.69 EPS this Y24.80% Inst Trans-12.86% Short Ratio1.64 Perf Half Y-88.26%
Book/sh-1.14 P/B- EPS next Y47.40% ROA-198.90% Target Price27.50 Perf Year-94.44%
Cash/sh0.01 P/C40.66 EPS next 5Y- ROE599.20% 52W Range0.46 - 10.50 Perf YTD-93.75%
Dividend- P/FCF- EPS past 5Y4.30% ROI-486.20% 52W High-95.24% Beta1.79
Dividend %- Quick Ratio0.20 Sales past 5Y119.90% Gross Margin90.50% 52W Low8.65% ATR0.10
Employees52 Current Ratio0.20 Sales Q/Q-66.70% Oper. Margin- RSI (14)27.07 Volatility10.60% 9.89%
OptionableYes Debt/Eq- EPS Q/Q-9.40% Profit Margin- Rel Volume0.66 Prev Close0.50
ShortableYes LT Debt/Eq- EarningsNov 20 AMC Payout- Avg Volume300.13K Price0.50
Recom2.00 SMA20-9.31% SMA50-70.14% SMA200-87.57% Volume195,952 Change-0.97%
Feb-16-18Downgrade Maxim Group Buy → Hold
Jan-19-18Initiated H.C. Wainwright Buy $2.50
Jul-27-17Reiterated Maxim Group Buy $6 → $2
Dec-31-15Reiterated Maxim Group Buy $8 → $6
Sep-05-14Upgrade Maxim Group Hold → Buy $3 → $7
Jul-09-14Downgrade Maxim Group Buy → Hold $7 → $3
May-01-14Reiterated Maxim Group Buy $9 → $7
Nov-19-13Reiterated Maxim Group Buy $7 → $9
Jan-31-13Initiated Maxim Group Buy $7
Sep-11-12Initiated Brean Murray Buy $7
Nov-05-18 05:10PM  Intellipharmaceutics Announces Resignation of Chief Financial Officer ACCESSWIRE
Oct-26-18 08:00AM  Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements ACCESSWIRE -5.98%
Oct-16-18 07:05PM  Intellipharmaceutics Announces Closing of US $14.3 Million Underwritten Public Offering ACCESSWIRE
Oct-15-18 05:15PM  Intellipharmaceutics Announces Third Quarter 2018 Results ACCESSWIRE
Oct-12-18 03:09PM  Don't Fixate On Market Woes, Just Make Your Trades Benzinga -21.00%
06:40AM  Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering FSCWire
06:15AM  Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering ACCESSWIRE
Oct-10-18 10:20PM  Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER FSCWire -21.80%
10:20PM  Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER ACCESSWIRE
Oct-01-18 08:00AM  Intellipharmaceutics Regains Compliance with NASDAQ Minimum Bid Price Requirement; Also Receives Requested Extension from NASDAQ Panel ACCESSWIRE
Sep-13-18 09:05AM  Intellipharmaceutics Announces One-for-10 Reverse Stock Split ACCESSWIRE
Sep-11-18 07:15AM  Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing ACCESSWIRE
Jul-25-18 07:20AM  Blog Exposure - Cambrex Announces Halo Pharma Acquisition ACCESSWIRE
Jul-17-18 05:05AM  Intellipharmaceutics: Fiscal 2Q Earnings Snapshot Associated Press
Jul-16-18 05:00PM  Intellipharmaceutics Announces Second Quarter 2018 Results ACCESSWIRE -6.04%
Jun-08-18 05:20PM  Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ ACCESSWIRE +5.08%
May-22-18 04:00PM  Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing ACCESSWIRE
May-16-18 08:00AM  Intellipharmaceutics Reports Director Election Results ACCESSWIRE
May-08-18 08:00AM  Intellipharmaceutics Announces Start of Intranasal Human Abuse Liability Studies for Oxycodone ER ACCESSWIRE +20.78%
Apr-27-18 08:00AM  Intellipharmaceutics Files Appeal to Nasdaq Delisting Determination ACCESSWIRE
07:20AM  Wired News Asterias Biotherapeutics: Clinical Grade Lot Released to Support Dosing of Subjects in First Clinical Study of AST-VAC2 in Non-Small Cell Lung Cancer ACCESSWIRE
Apr-23-18 05:00PM  Intellipharmaceutics Receives Delisting Determination from NASDAQ Staff; Company to Request Hearing ACCESSWIRE
Apr-16-18 05:00PM  Intellipharmaceutics Announces First Quarter 2018 Results ACCESSWIRE
Mar-21-18 04:30PM  Intellipharmaceutics Announces Closing of US$1.8 Million Financing ACCESSWIRE
Mar-19-18 02:55PM  Intellipharmaceutics Announces US$1.8 Million Registered Direct Offering ACCESSWIRE -5.90%
Mar-16-18 07:45PM  Intellipharmaceutics Announces Closing of US$3.5 Million Financing ACCESSWIRE
Mar-14-18 09:00AM  Intellipharmaceutics Announces US$3.5 Million Registered Direct Offering ACCESSWIRE +15.77%
Feb-16-18 06:00AM  Intellipharmaceutics Announces Fiscal Year 2017 Results ACCESSWIRE -9.32%
Feb-13-18 05:30PM  Intellipharmaceutics Sets Earnings Release Date for Year End 2017 Results ACCESSWIRE
Feb-09-18 08:00AM  Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program ACCESSWIRE
Jan-24-18 08:00AM  Intellipharmaceutics Provides Operational Update GlobeNewswire
Dec-05-17 08:00AM  Intellipharmaceutics Announces Receipt of Nasdaq Notice GlobeNewswire
Nov-30-17 10:45AM  Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical GlobeNewswire
Nov-08-17 07:30AM  Corporate News Blog - Valeant Pharma Sells Sprout Pharmas Subsidiary Back to Original Shareholders ACCESSWIRE
Oct-13-17 05:45PM  Intellipharmaceutics Announces Closing of US$4 Million Financing GlobeNewswire
09:03AM  Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017 Capital Cube
Oct-11-17 09:05AM  New Strong Sell Stocks for October 11th Zacks -6.09%
08:00AM  Intellipharmaceutics Announces US$4 Million Registered Direct Offering GlobeNewswire
Oct-10-17 05:26PM  Intellipharmaceutics reports 3Q loss Associated Press
05:20PM  Intellipharmaceutics Announces Third Quarter 2017 Results GlobeNewswire
Sep-29-17 01:46PM  DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm ACCESSWIRE -7.46%
10:38AM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intellipharmaceutics International Inc. - IPCI PR Newswire
10:17AM  DEADLINE TODAY: Goldberg Law PC Announces a Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm PR Newswire
10:07AM  DEADLINE TODAY: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI) ACCESSWIRE
10:07AM  DEADLINE TODAY - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
Sep-28-17 12:12PM  DEADLINE TOMORROW: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:01AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
09:57AM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
Sep-26-17 05:08PM  DEADLINE FRIDAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
10:35AM  SHAREHOLDER ALERT: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI) ACCESSWIRE
10:13AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
Sep-25-17 01:05PM  DEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire +18.52%
10:57AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
10:00AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
07:38AM  FDA declines to approve Intellipharma's opioid painkiller Reuters
07:09AM  FDA declines to approve Intellipharma's opioid painkiller Reuters
07:00AM  Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA GlobeNewswire
Sep-23-17 08:45AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
Sep-20-17 05:54PM  DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
05:10PM  Intellipharmaceutics Announces Receipt of Nasdaq Notice GlobeNewswire
11:26AM  IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017 ACCESSWIRE
Sep-19-17 01:30PM  10-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
12:21PM  ALERT: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI) ACCESSWIRE
10:26AM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
Sep-18-17 08:11PM  DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -5.50%
04:50PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in IntelliPharmaCeutics International Inc. to Contact The Firm ACCESSWIRE
11:12AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
Sep-16-17 09:55AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
Sep-15-17 11:35PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:30AM  IPCI EXPANDED CLASS PERIOD: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017 ACCESSWIRE
Sep-14-17 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
05:48PM  DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:17AM  EXPANDED CLASS: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
Sep-13-17 06:18PM  IPCI ALERT: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors of Important Deadline in Class Action IPCI GlobeNewswire
03:47PM  SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:15AM  IPCI EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017 ACCESSWIRE
Sep-12-17 09:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPC ACCESSWIRE
04:39PM  UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:05AM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and the Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
10:40AM  INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
Sep-11-17 04:45PM  DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
11:43AM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI) ACCESSWIRE
Sep-09-17 10:45AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
Sep-08-17 11:53PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
06:35PM  INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Intellipharmaceutics International Inc. Investors (IPCI) Business Wire
02:00PM  IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017 ACCESSWIRE
Sep-07-17 04:17PM  READ NOW: Monteverde & Associates PC Reminds IntelliPharmaCeutics International Inc. Shareholders with Losses in Excess of $100,000 To Contact the Firm Immediately - IPCI ACCESSWIRE +6.44%
02:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
01:18PM  UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
10:35AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017 ACCESSWIRE
Sep-06-17 05:10PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In IntelliPharmaCeutics International Inc. To Contact The Firm ACCESSWIRE
03:52PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
03:31PM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI) ACCESSWIRE
Sep-05-17 05:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCI ACCESSWIRE
02:35PM  Intellipharmaceutics Provides Operational Update GlobeNewswire
02:01PM  APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
10:56AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI ACCESSWIRE
07:20AM  Corporate News Blog - Intellipharmaceutics International Announces Appointment of CFO ACCESSWIRE
Sep-02-17 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline Business Wire
Sep-01-17 11:56PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.